These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 21507677)
1. CXCL2 mediates lipopolysaccharide-induced osteoclastogenesis in RANKL-primed precursors. Ha J; Lee Y; Kim HH Cytokine; 2011 Jul; 55(1):48-55. PubMed ID: 21507677 [TBL] [Abstract][Full Text] [Related]
2. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972 [TBL] [Abstract][Full Text] [Related]
3. CXC chemokine ligand 2 induced by receptor activator of NF-kappa B ligand enhances osteoclastogenesis. Ha J; Choi HS; Lee Y; Kwon HJ; Song YW; Kim HH J Immunol; 2010 May; 184(9):4717-24. PubMed ID: 20357249 [TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of osteoclast differentiation and bone resorption by sauchinone. Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption. Park CK; Kim HJ; Kwak HB; Lee TH; Bang MH; Kim CM; Lee Y; Chung DK; Baek NI; Kim J; Lee ZH; Kim HH Int Immunopharmacol; 2007 Dec; 7(12):1507-16. PubMed ID: 17920527 [TBL] [Abstract][Full Text] [Related]
7. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351 [TBL] [Abstract][Full Text] [Related]
8. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling. Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790 [TBL] [Abstract][Full Text] [Related]
9. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts. Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700 [TBL] [Abstract][Full Text] [Related]
10. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity. Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185 [TBL] [Abstract][Full Text] [Related]
12. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Li L; Sapkota M; Kim SW; Soh Y Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730 [TBL] [Abstract][Full Text] [Related]
13. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway. Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114 [TBL] [Abstract][Full Text] [Related]
14. Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NF kappaB and downregulating NFATc1 and c-Fos. Ha J; Choi HS; Lee Y; Lee ZH; Kim HH Int Immunopharmacol; 2009 Jun; 9(6):774-80. PubMed ID: 19285574 [TBL] [Abstract][Full Text] [Related]
15. The novel isoflavone derivatives inhibit RANKL-induced osteoclast formation. Tang CH; Chang CS; Tan TW; Liu SC; Liu JF Eur J Pharmacol; 2010 Dec; 648(1-3):59-66. PubMed ID: 20850430 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways. Choi HJ; Park YR; Nepal M; Choi BY; Cho NP; Choi SH; Heo SR; Kim HS; Yang MS; Soh Y Eur J Pharmacol; 2010 Jun; 636(1-3):28-35. PubMed ID: 20353769 [TBL] [Abstract][Full Text] [Related]
17. Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice. Lee JW; Kobayashi Y; Nakamichi Y; Udagawa N; Takahashi N; Im NK; Seo HJ; Jeon WB; Yonezawa T; Cha BY; Woo JT Biochem Pharmacol; 2010 Aug; 80(3):352-61. PubMed ID: 20412788 [TBL] [Abstract][Full Text] [Related]
18. Dual modulation of osteoclast differentiation by lipopolysaccharide. Zou W; Bar-Shavit Z J Bone Miner Res; 2002 Jul; 17(7):1211-8. PubMed ID: 12096834 [TBL] [Abstract][Full Text] [Related]
19. Membrane-bound CD40 ligand on T cells from mice injected with lipopolysaccharide accelerates lipopolysaccharide-induced osteoclastogenesis. Yokoyama M; Ukai T; Ayon Haro ER; Kishimoto T; Yoshinaga Y; Hara Y J Periodontal Res; 2011 Aug; 46(4):464-74. PubMed ID: 21521224 [TBL] [Abstract][Full Text] [Related]
20. The inhibition of RANKL-induced osteoclastogenesis through the suppression of p38 signaling pathway by naringenin and attenuation of titanium-particle-induced osteolysis. Wang W; Wu C; Tian B; Liu X; Zhai Z; Qu X; Jiang C; Ouyang Z; Mao Y; Tang T; Qin A; Zhu Z Int J Mol Sci; 2014 Nov; 15(12):21913-34. PubMed ID: 25464380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]